

Board Meeting  
January 31, 2019

ROLL CALL

PURCHASE RECOMMENDATIONS

The "Purchase Recommendations and Renewal Options" are presented by university, and a Summary from "Appropriated Funds" (i.e., from State appropriations to the university) and from "Institutional Funds" is included. The latter term is used here to designate funds received by the university under contracts with the United States Government; contracts with private corporations and other organizations, from foundation grants, and grants from corporations and other donors; and university revolving funds authorized by law. The Summary also indicates a total amount by university.

The Board action recommended in this item complies in all material respects with applicable State and federal laws, University of Illinois Statutes, The General Rules Concerning University Organization and Procedure, and Board of Trustees policies and directives.

The Assistant Vice President for Procurement Services has proposed and the Vice President, Chief Financial Officer recommends the following purchases. Unless otherwise specified, the purchase in each case is recommended on the basis of the lowest acceptable bid.

The President of the University concurs.

**PURCHASES RECOMMENDED**

<b>Chicago</b>	
1	Unit University of Illinois Hospital
Item	Purchase of oral medication Tecfidera (tecfidera dimethyl fumarate) for the period of February 1, 2019 through June 30, 2022.
Cost	\$4,500,000 (estimated)
Vendors	Biogen Direct, Cambridge, MA
	This purchase is exempt from competitive selection procedures in accordance with the Illinois Procurement Code Section 30 ILCS 500/1-13(b-

5) regarding contracts for medical supplies and services necessary for the delivery of care and treatment.

Tecfidera -Dimethyl fumarate (Tecfidera) is an oral medication used to treat relapsing-remitting multiple sclerosis (RRMS). Biogen Direct is the exclusive distributor; without the purchase patient care and revenue could be compromised.

The pricing is the same as the previous contract. Biogen Direct holds the patent to this medication. No discounts are available.

2 Unit University of Illinois Hospital

---

Item Purchase of implantable neurostimulation system for the period of February 28, 2019 through June 30, 2023.

Cost \$10,000,000 (estimated)

Vendors Medtronic, USA

This purchase is exempt from competitive selection procedures in accordance with the Illinois Procurement Code Section 30 ILCS 500/1-13(b-5) regarding contracts for medical supplies and services necessary for the delivery of care and treatment.

The spinal cord stimulator is similar to a pacemaker in that is implanted under the skin. Spinal cord stimulation provides pain relief by modifying the pain messages before they reach the brain. The neurostimulator sends out mild electrical pulses that reach the brain faster than the pain signal can arrive.

Negotiations have resulted in an average discount of three percent (3%) off of list price. The discount is the same off of list price as the previous contract. Medtronic holds the patents to this technology.

<b>SUMMARY OF PURCHASES</b>	
Chicago	\$14,500,000
Recommended from Institutional Funds	
Grand Total	\$14,500,000